On the contrary, lorcaserin, a serotonin 2C receptor agonist, should be avoided in patients treated with selective serotonin reuptake inhibitors (SSRIs) given the increased risk of serotonin syndrome [57]. The gene discussed is HTR2C; the disease is serotonin syndrome.